Tags

Type your tag names separated by a space and hit enter

Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia.
J Urol. 2001 Oct; 166(4):1358-63.JU

Abstract

PURPOSE

The long-term efficacy and safety of 0.4 mg. tamsulosin once daily were assessed in patients with lower urinary tract symptoms/benign prostatic hyperplasia treated for up to 4 years.

MATERIALS AND METHODS

A total of 516 patients were enrolled from 2 European open label studies that were extensions of 3 double-blind controlled studies.

RESULTS

Significant improvement in maximum urine flow and total Boyarsky symptom score during the controlled trials was sustained throughout the extension study for up to 4 years in patients who remained on therapy. The increase in mean maximum urine flow from baseline was 1.2 to 2.2 ml. per second (p <0.001) and it remained 11.5 to 12 ml. per second during followup. Total Boyarsky symptom score was decreased from baseline by 4.1 to 4.7 points (p <0.001). The incidence of treatment responders, defined as a 25% or greater decrease in total symptom score, remained stable throughout the 4-year period. Increasing the dose of tamsulosin from 0.4 to 0.8 mg. seemed to have no substantial additional benefit. During the 4 years of treatment 26% of patients had side effects that were considered possibly or probably drug related. However, only 5% of patients discontinued treatment because of drug related side effects. No clinically significant changes in blood pressure or pulse rate occurred during the study.

CONCLUSIONS

Long-term treatment with tamsulosin is safe and well tolerated in patients with lower urinary tract symptoms/benign prostatic hyperplasia. Improved efficacy was sustained during 4 years of followup.

Authors+Show Affiliations

Erasmus University Hospital, Brussels, Belgium.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11547074

Citation

Schulman, C C., et al. "Long-term Use of Tamsulosin to Treat Lower Urinary Tract Symptoms/benign Prostatic Hyperplasia." The Journal of Urology, vol. 166, no. 4, 2001, pp. 1358-63.
Schulman CC, Lock TM, Buzelin JM, et al. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol. 2001;166(4):1358-63.
Schulman, C. C., Lock, T. M., Buzelin, J. M., Boeminghaus, F., Stephenson, T. P., & Talja, M. (2001). Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. The Journal of Urology, 166(4), 1358-63.
Schulman CC, et al. Long-term Use of Tamsulosin to Treat Lower Urinary Tract Symptoms/benign Prostatic Hyperplasia. J Urol. 2001;166(4):1358-63. PubMed PMID: 11547074.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. AU - Schulman,C C, AU - Lock,T M, AU - Buzelin,J M, AU - Boeminghaus,F, AU - Stephenson,T P, AU - Talja,M, AU - ,, PY - 2001/9/8/pubmed PY - 2002/1/5/medline PY - 2001/9/8/entrez SP - 1358 EP - 63 JF - The Journal of urology JO - J Urol VL - 166 IS - 4 N2 - PURPOSE: The long-term efficacy and safety of 0.4 mg. tamsulosin once daily were assessed in patients with lower urinary tract symptoms/benign prostatic hyperplasia treated for up to 4 years. MATERIALS AND METHODS: A total of 516 patients were enrolled from 2 European open label studies that were extensions of 3 double-blind controlled studies. RESULTS: Significant improvement in maximum urine flow and total Boyarsky symptom score during the controlled trials was sustained throughout the extension study for up to 4 years in patients who remained on therapy. The increase in mean maximum urine flow from baseline was 1.2 to 2.2 ml. per second (p <0.001) and it remained 11.5 to 12 ml. per second during followup. Total Boyarsky symptom score was decreased from baseline by 4.1 to 4.7 points (p <0.001). The incidence of treatment responders, defined as a 25% or greater decrease in total symptom score, remained stable throughout the 4-year period. Increasing the dose of tamsulosin from 0.4 to 0.8 mg. seemed to have no substantial additional benefit. During the 4 years of treatment 26% of patients had side effects that were considered possibly or probably drug related. However, only 5% of patients discontinued treatment because of drug related side effects. No clinically significant changes in blood pressure or pulse rate occurred during the study. CONCLUSIONS: Long-term treatment with tamsulosin is safe and well tolerated in patients with lower urinary tract symptoms/benign prostatic hyperplasia. Improved efficacy was sustained during 4 years of followup. SN - 0022-5347 UR - https://www.unboundmedicine.com/medline/citation/11547074/Long_term_use_of_tamsulosin_to_treat_lower_urinary_tract_symptoms/benign_prostatic_hyperplasia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-5347(05)65769-2 DB - PRIME DP - Unbound Medicine ER -